Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
| Operating expenses | ||||
| Research and Development Expense (Income) | $ 3,182 | $ 1,096 | $ 5,608 | $ 8,094 |
| General and administrative | 1,880 | 457 | 4,121 | 2,359 |
| Total operating expenses | 5,062 | 1,553 | 9,729 | 10,453 |
| Loss from operations | (5,062) | (1,553) | (9,729) | (10,453) |
| Other income | ||||
| Other income | 167 | 71 | 231 | 657 |
| Net loss | $ (6,775) | $ (2,832) | $ (13,483) | $ (1,848) |
| Net loss per share | ||||
| Basic (in dollars per share) | $ (1.22) | $ (0.53) | $ (2.46) | $ (0.42) |
| Weighted average number of common shares outstanding | ||||
| Basic (in shares) | 5,720,009 | 5,720,009 | 5,720,009 | 5,720,009 |
| Pieris Pharmaceuticals, Inc. [Member] | ||||
| Revenue | ||||
| Customer revenue | $ 0 | $ 15,569 | $ 6 | $ 37,665 |
| Collaboration revenue | 0 | 3,951 | 47 | 3,846 |
| Total revenue | 0 | 19,520 | 53 | 41,511 |
| Operating expenses | ||||
| Research and Development Expense (Income) | (446) | 9,595 | 1,523 | 37,347 |
| General and administrative | 3,581 | 6,839 | 11,145 | 14,526 |
| Asset impairment | 0 | 14,893 | 0 | 14,893 |
| Total operating expenses | 3,135 | 31,327 | 12,668 | 66,766 |
| Loss from operations | (3,135) | (11,807) | (12,615) | (25,255) |
| Other income | ||||
| Interest income | 169 | 549 | 610 | 1,396 |
| Grant income | 0 | 0 | 0 | 3,612 |
| Other income | 79 | 506 | 636 | 288 |
| Net loss | (2,887) | (10,752) | (11,369) | (19,959) |
| Other comprehensive income loss: | ||||
| Foreign currency translation | 120 | (204) | (343) | (159) |
| Unrealized gain (loss) on available-for-sale securities | 0 | 2 | (1) | 74 |
| Comprehensive loss | $ (2,767) | $ (10,954) | $ (11,713) | $ (20,044) |
| Net loss per share | ||||
| Basic (in dollars per share) | $ (2.19) | $ (8.7) | $ (8.84) | $ (18.33) |
| Diluted (in dollars per share) | $ (2.19) | $ (8.7) | $ (8.84) | $ (18.33) |
| Weighted average number of common shares outstanding | ||||
| Basic (in shares) | 1,320,000 | 1,236,000 | 1,285,000 | 1,089,000 |
| Diluted (in shares) | 1,320,000 | 1,236,000 | 1,285,000 | 1,089,000 |
| X | ||||||||||
- Definition The amount of research and development expense (income). No definition available.
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in income from government assistance. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as nonoperating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|